Angle PLC Parsortix system showcased at ACTC conference
September 29 2023 - 2:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
29 September 2023
For immediate release 29 September 2023
ANGLE plc ("the Company")
PARSORTIX SYSTEM SHOWCASED AT 'Advances in Circulating Tumor
Cells' conference
Nine poster presentations utilising the Parsortix system in six
cancer types all received positive feedback
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is pleased to announce its participation at the 6(th)
Advances in Circulating Tumor Cells (ACTC) conference held in
Greece from 20-23 September 2023.
The conference brought together translational researchers and
industry participants to discuss the latest developments and
clinical applications of liquid biopsy and advances in precision
oncology. This included the presentation of nine posters showcasing
the Parsortix(R) system in six cancer types across eight
independent study centres.
Conference highlights utilising the Parsortix system
include:
-- A study by the Fondazione IRCCS Istituto Nazionale dei
Tumori, Italy, investigating the relevance of CTC biomarkers for
monitoring treatment response in Non-Small Cell Lung Cancer
(NSCLC). The study in 60 patients, found that CTC-based biomarkers
were predictive of treatment resistance and that PD-L1+ CTCs might
be used to select patients for immunotherapy.
-- Three posters in lung, pancreatic and bone cancer
respectively, reporting on the potential clinical significance of
mesenchymal CTCs which would have been missed if traditional
epithelial label-dependent CTC capture methods had been
utilised.
-- Two posters showcasing dual analysis of CTCs and ctDNA,
highlighting the growing interest in the addition of CTC analysis
to ctDNA assays as a means to provide information on gene
expression (RNA) and proteins, with data providing increasing
evidence that RNA analysis can provide clinicians with additional
targeted treatment options.
ANGLE Chief Scientific Officer, Karen Miller, commented:
"We were pleased to see the Parsortix system being showcased at
the ACTC conference by translational researchers from seven
European countries in patients across a breadth of cancers
including lung, breast, prostate, pancreatic, thyroid and bone.
ANGLE received extremely positive feedback on the Parsortix system
and, in particular, our plans for new assays to provide content for
the Parsortix system. We look forward to expanding our
translational research use through our international distributors
whilst continuing to grow our biopharma services business."
For further information:
ANGLE plc
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director +44 (0) 1483 343434
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories in the UK and the United States. Services include
custom made assay development and clinical trial testing for
pharma.
Over 80 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEVLFLXKLEBBZ
(END) Dow Jones Newswires
September 29, 2023 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024